Ashwini Kumar Esnakula

Honored to be presenting at #DDW2023 along with my esteem co-presenters Drs. Hirano, Pham, @MFeelyDO @AKE_Path @DocStanich, with our wonderful moderator @DiptiKaramchan2 at Session: AGA Key to Optimal Patient Care: Good Clinician-Pathologist Communication. @USGIPS @DDWMeeting

Started 2nd EUS-chemoablation expanded access protocol (EAP) with LSAM-PTX (Sub-micronized Paclitaxel) for BD-IPMNs. Encouraging data from preceding (1st) EAP N=6 BD-IPMNs 50-90% ⏬ volume 31-80% ⏬ surface area Loss of pathogenic mutations-83% Fibrosis & calcification-83%

After 6 months of clearing all regulatory issues - excited to start our prospective study evaluating EUS-RFA in the management of BD-IPMNs. The ERASE study (E⃣US-guided R⃣FA of PCLs - A⃣ S⃣afety & E⃣fficacy trial) Pre-trial case (below) with a great response.

Happy Friday! Our first #IGCSPathPoll is: Endometrial tumor in a postmenopausal patient with thromboembolism...

EUS-guided chemoablation with LSAM-PTX (NanoPac). Excellent resolution of a 4cm BD-IPMN. Immediate & a year later - continued durable response. Confident ablation > possible with a highly accurate diagnosis of cysts by EUS-endomicroscopy (nCLE) & fluid molecular analysis (NGS)

A warm welcome to our incoming PGY-1 residents- Luke Bushrow, Himani Kumar, Aaron Chow and Ryan Reagans!

You know how you’ve always wanted to live in FL and dream of working with awesome folks like @DHGGIpath and @XiuliLiu1? Now’s your chance! We have an unexpected opening in our GI liver fellowship for 2020. See link. #GIpath #pathology pathology.ufl.edu/education/fell…

First it was the CAP abstract book and now this! It has been a good year for cover photos. @PediDevPath Thank you for the selection! Article on Sclerosing Epithelioid Fibrosarcoma of Bone with EWSR1-CREB3L3 fusion here: journals.sagepub.com/doi/full/10.11… #pedipath @SocPediPath @LeaSurrey